SCI Pharmtech, Inc. (TPE: 4119)

Market Cap	10.46B
Revenue (ttm)	1.25B
Net Income (ttm)	138.47M
Shares Out	119.51M
EPS (ttm)	1.19
PE Ratio	73.37
Forward PE	n/a
Dividend	1.25 (1.43%)
Ex-Dividend Date	Jul 1, 2024

Volume	139,921
Open	87.00
Previous Close	86.50
Day's Range	86.50 - 88.00
52-Week Range	84.80 - 100.50
Beta	-0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About SCI Pharmtech

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexmethylphenidate HCl. The company’s intermedi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 239
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2023, SCI Pharmtech's revenue was 1.20 billion, an increase of 33.83% compared to the previous year's 899.74 million. Earnings were 294.72 million, a decrease of -4.55%.